A Study Comparing Conventional Dose to High-Dose Treatment with Stem Cell Transplant in Myeloma

What we are studying

In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.

Who we are studying

• Men and Women
• Races:
  • White
  • African American
  • Asian
  • American Indian or Alaska Native
  • Native Hawaiian or Pacific Islander
  • Other
• All Ethnicities
• Ages 18 - 65

Eligibility Criteria

• Diagnosed with multiple myeloma
• No history of other cancer

What is involved

• Study participation will last 3-6 years
• Physical Exams
• Blood Tests
• Heart Tests
• Lung Tests
• Bone Marrow Tests
• Treatment with lenalidomide and bortezomib and dexamethasone
• Peripheral blood stem cell transplant

Compensation:

None

Contact Information

Study Coordinator

Scarlett Hutchens

Email

snhutche@wakehealth.edu

Phone

336-713-6915